Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection
Chronic hepatitis B (CHB) is a potentially life-threatening and prevalent disease worldwide. Far from attaining the ultimate treatment goal, hepatitis B virus (HBV) infection eradication, the two current therapeutic options aim to prevent progression to end-stage liver disease, maintaining long-term...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/2022/3890309 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849396585663823872 |
|---|---|
| author | Joana Vasconcelos João Domingos Lia Bastos Teresa Baptista Kamal Mansinho |
| author_facet | Joana Vasconcelos João Domingos Lia Bastos Teresa Baptista Kamal Mansinho |
| author_sort | Joana Vasconcelos |
| collection | DOAJ |
| description | Chronic hepatitis B (CHB) is a potentially life-threatening and prevalent disease worldwide. Far from attaining the ultimate treatment goal, hepatitis B virus (HBV) infection eradication, the two current therapeutic options aim to prevent progression to end-stage liver disease, maintaining long-term suppression of HBV replication. Pegylated interferon-α (PEG-INFα) is often poorly tolerated and disregarded considering the orally administered nucleos(t)ide analogues. However, PEG-INFα may achieve similar treatment endpoints with a finite course of treatment. We report a case of PEG-INFα-treated CHB that attained sustained off-treatment virological response with only 16 weeks of treatment, with loss of both HBeAg and HBsAg (this latter the optimal treatment endpoint). |
| format | Article |
| id | doaj-art-b1d71b949b6949efa8eaf56e2cc904cb |
| institution | Kabale University |
| issn | 2090-6633 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Infectious Diseases |
| spelling | doaj-art-b1d71b949b6949efa8eaf56e2cc904cb2025-08-20T03:39:18ZengWileyCase Reports in Infectious Diseases2090-66332022-01-01202210.1155/2022/3890309Pegylated Interferon Alpha for Chronic Hepatitis B Virus InfectionJoana Vasconcelos0João Domingos1Lia Bastos2Teresa Baptista3Kamal Mansinho4Infectious Diseases DepartmentInfectious Diseases DepartmentInfectious Diseases DepartmentInfectious Diseases DepartmentInfectious Diseases DepartmentChronic hepatitis B (CHB) is a potentially life-threatening and prevalent disease worldwide. Far from attaining the ultimate treatment goal, hepatitis B virus (HBV) infection eradication, the two current therapeutic options aim to prevent progression to end-stage liver disease, maintaining long-term suppression of HBV replication. Pegylated interferon-α (PEG-INFα) is often poorly tolerated and disregarded considering the orally administered nucleos(t)ide analogues. However, PEG-INFα may achieve similar treatment endpoints with a finite course of treatment. We report a case of PEG-INFα-treated CHB that attained sustained off-treatment virological response with only 16 weeks of treatment, with loss of both HBeAg and HBsAg (this latter the optimal treatment endpoint).http://dx.doi.org/10.1155/2022/3890309 |
| spellingShingle | Joana Vasconcelos João Domingos Lia Bastos Teresa Baptista Kamal Mansinho Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection Case Reports in Infectious Diseases |
| title | Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection |
| title_full | Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection |
| title_fullStr | Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection |
| title_full_unstemmed | Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection |
| title_short | Pegylated Interferon Alpha for Chronic Hepatitis B Virus Infection |
| title_sort | pegylated interferon alpha for chronic hepatitis b virus infection |
| url | http://dx.doi.org/10.1155/2022/3890309 |
| work_keys_str_mv | AT joanavasconcelos pegylatedinterferonalphaforchronichepatitisbvirusinfection AT joaodomingos pegylatedinterferonalphaforchronichepatitisbvirusinfection AT liabastos pegylatedinterferonalphaforchronichepatitisbvirusinfection AT teresabaptista pegylatedinterferonalphaforchronichepatitisbvirusinfection AT kamalmansinho pegylatedinterferonalphaforchronichepatitisbvirusinfection |